Rheumatoid Arthritis Management Guidelines

Initial Treatment and Disease Assessment

The American College of Rheumatology recommends initiating methotrexate as first-line therapy immediately upon diagnosis, rapidly escalating to 20-25 mg weekly with folic acid supplementation 1, 2, 3
Start at 7.5-10 mg weekly and escalate to the optimal dose of 20-25 mg weekly within 4-6 weeks 3
Add short-term low-dose glucocorticoids (≤10 mg/day prednisone equivalent) as bridging therapy for patients with moderate or high disease activity 2, 3
Taper glucocorticoids within 3 months and discontinue within 1-2 years to avoid serious adverse effects including cataracts, osteoporosis, and cardiovascular disease 1, 3

For patients unable to tolerate methotrexate, use leflunomide, sulfasalazine, or hydroxychloroquine as alternative conventional synthetic DMARDs 1, 2
Add a biologic DMARD (TNF inhibitor preferred) combined with methotrexate for patients with poor prognostic features 2, 3
Poor prognostic features include: rheumatoid factor positivity, anti-CCP antibody positivity, elevated acute phase reactants, high disease activity, or early erosive disease 2
First-line biologic therapy should be a TNF inhibitor (adalimumab, certolizumab, etanercept, golimumab, or infliximab) combined with methotrexate 2, 3

Screen all patients for tuberculosis, hepatitis B and C, active infections, congestive heart failure, and history of malignancy before starting any biologic DMARD 2, 3
Do not use biologics in patients with active serious infections 2
Discontinue biologic therapy immediately if a serious infection develops 2
Use non-TNF inhibitor biologics or targeted synthetic DMARDs instead of TNF inhibitors in patients with heart failure (NYHA Class III-IV) 3

All patients should engage in consistent exercise as part of their RA management plan (strong recommendation) 4, 5
Exercise, rehabilitation, diet, and additional integrative interventions should be used in conjunction with DMARDs, not as replacements 4, 5
For patients achieving sustained remission (at least 6 months of low disease activity), consider cautious de-escalation of therapy through shared decision-making 1, 2, 3
Approximately 15-25% of patients may achieve sustained drug-free remission 1, 2

Delaying DMARD initiation leads to irreversible joint damage and worse long-term outcomes - start methotrexate immediately upon diagnosis 1
Inadequate methotrexate dosing - must escalate to 20-25 mg weekly, not stopping at lower doses 1, 3
Insufficient treatment trial duration - allow 3 months at optimal dose before concluding treatment failure 2, 3
Prolonged glucocorticoid use - must taper within 3 months and discontinue within 1-2 years 1, 3
Failure to escalate therapy when treatment targets are not met - reassess every 3 months and escalate immediately if not at target 2, 3
Overlooking mandatory safety screening - always screen for tuberculosis, hepatitis B/C, and assess comorbidities before starting biologics 2, 3